Central Bank & Trust Co. Sells 660 Shares of Danaher Co. (NYSE:DHR)

Central Bank & Trust Co. decreased its stake in shares of Danaher Co. (NYSE:DHR) by 9.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,648 shares of the conglomerate’s stock after selling 660 shares during the period. Central Bank & Trust Co.’s holdings in Danaher were worth $1,526,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Decker Retirement Planning Inc. bought a new position in shares of Danaher during the 4th quarter valued at $31,000. Teachers Insurance & Annuity Association of America bought a new position in Danaher in the third quarter valued at about $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the third quarter worth about $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter valued at about $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter valued at about $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

NYSE:DHR opened at $238.41 on Tuesday. The business’s 50-day moving average is $234.85 and its 200 day moving average is $253.51. Danaher Co. has a 12 month low of $222.53 and a 12 month high of $281.70. The company has a market capitalization of $172.20 billion, a P/E ratio of 45.50, a P/E/G ratio of 4.23 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the firm earned $2.02 EPS. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, equities research analysts forecast that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Analyst Ratings Changes

A number of research firms recently issued reports on DHR. Stifel Nicolaus raised their price objective on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. KeyCorp boosted their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Finally, Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research note on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.